Formulation Engineering Standards

[[1. POSITION]]
Endgame formulations are engineered as modular system components within a unified performance infrastructure.

Products are not designed as isolated blends. They are engineered to function independently while integrating without redundancy across the wider system.

Every ingredient must justify its presence within both the individual product and the broader architecture.

This standard governs ingredient selection, dose strategy, pathway targeting, overlap control, and stack integrity across Life Support and Performance Systems.

[[2. SYSTEM ARCHITECTURE ALIGNMENT]]
All formulas must align with their designated system class and structural role within the Endgame ecosystem.

Life Support Systems:
■ Class I - Baseline Stability: Designed for sustained daily use to maintain resilience and tolerance under ongoing physiological demand.
■ Class II - Targeted Tolerance: Increase protection in specific physiological domains when stress is concentrated.
■ Class III - Corrective Intervention: Short-term tools used only when markers themselves require direct correction.

Performance Systems:
■ Engineered for mechanistic completeness and perceptible output where relevant.
■ Multi-pathway activation permitted when each pathway meaningfully contributes.
■ Designed for controlled aggression and performance execution, not chaotic stimulation.

[[3. INGREDIENT INCLUSION STANDARD]]
An ingredient must satisfy at least three of the following criteria:
■ Supported by human clinical data at relevant dose
■ Mechanistically necessary within the formula
■ Contributes to measurable capability density
■ Compatible with stack architecture
■ Demonstrates acceptable cost-to-effect ratio
■ Regulatory viable across intended markets
■ Does not materially degrade compliance

<<Ingredients are not included for trend alignment, marketing optics, or defensive label padding.>>

[[4. MECHANISTIC REINFORCEMENT POLICY]]
Multi-angle targeting of a physiological outcome is permitted when:
■ The outcome is performance-critical
■ Complementary pathways enhance reliability
■ Each mechanism contributes meaningfully at a relevant dose

<<Decorative redundancy and subclinical analog duplication are prohibited.>>

[[5. BIOAVAILABILITY & FORM SELECTION]]
Ingredient form is selected on the basis of bioavailability, not cost per kilogram of raw material.

Where mineral forms exist with meaningfully different absorption profiles, the higher-bioavailability form is used. Chelated forms, including bisglycinate and picolinate variants, are preferred over oxide and sulphate equivalents where absorption data supports the selection.

Labels declare delivered elemental dose with form noted in parenthesis. Compound weight is not used as the primary dose declaration.

[[6. TRANSPARENCY & LABEL INTEGRITY]]
All ingredients are disclosed individually at their full dose.
Proprietary blend structures are not used. Every compound present in a formula is listed with its individual quantity.

[[7. DOSE PHILOSOPHY]]
Dose decisions are guided by:
■ Demonstrated effect size
■ Functional demand under elevated stress or training load
■ Long-term tolerability
■ Stack safety within the wider system

Where dual operating states exist, both must preserve mechanistic integrity and controlled output.

[[8. OVERLAP GOVERNANCE]]
Overlap is permitted only when:
■ It reinforces baseline protection
■ It increases tolerance margin
■ It enhances stack stability

Overlap is prohibited when:
■ It artificially fragments the catalogue
■ It inflates cumulative dose risk
■ It forces dependency on narrow SKUs

[[9. COMPLIANCE & PRACTICAL CONSTRAINTS]]
Formulas must account for capsule count sustainability, palatability, GI tolerance, and long-term adherence. Ingredients that meaningfully reduce compliance without delivering proportional benefit should be removed.

[[10. ESCALATION LOGIC]]
■ Base systems handle the majority of use cases.
■ Targeted SKUs increase tolerance under disproportionate stress.
■ Corrective tools intervene only when markers exceed acceptable range.
■ Escalation must reduce complexity, not create permanent stacking dependency.

[[11. ANTI-DRIFT COMMITMENT]]
Every reformulation or new SKU must strengthen system coherence and capability density.
If a change increases catalogue noise, redundancy, or fragility, it does not proceed.